
This study aims to assess the efficacy, safety, and tolerability of cotadutide in patients with type 2 diabetes mellitus and chronic kidney disease (CKD). In this phase 2a study (NCT03550378), patients were randomized 1:1 to once‐daily subcutaneous cotadutide. Participants receiving cotadutide had significant reductions in MMTT area under the glucose concentration–time curve (AUC), more time in the target glucose range on continuous glucose monitoring (+14.79% vs –21.23%, p = 0.001) and significant reductions in absolute body weight. This study established the efficacy of cotadutide in this patient population, with significantly improved postprandial glucose control and reduced bodyweight versus placebo. Reductions in UACR suggest potential benefits of cotadutide on kidney function, supporting further evaluation in larger, longer‐term clinical trials.
Like
Save
Share